LODOXAMIDE TREATMENT OF ALLERGIC CONJUNCTIVITIS

Lodoxamide is an antiallergic compound. The present study evaluated th e efficacy on clinical and cytological parameters and safety of topica l lodoxamide compared to placebo in the treatment of allergic conjunct ivitis. The trial, designed as double-blind, randomized, placebo-contr olled and parallel group treatment, was carried out in 30 patients, su ffering from seasonal allergic conjunctivitis due to grass pollen, dur ing the pollen season. Patients received lodoxamide tromethamine 0.1% eye drops or placebo eye drops, one drop in each eye t.i.d. for 4 week s. The clinical and cytological evidence was investigated by clinician s on admission and after 4 weeks' treatment. At the end of the trial, only the lodoxamide-treated group showed a significant clinical improv ement, associated with a reduction of inflammatory cells. No serious s ide effects were observed. The results show the clinical efficacy of l odoxamide in the treatment of pollen-induced allergic conjunctivitis. In addition, lodoxamide exerts its antiallergic activity by reducing i nflammatory infiltrate (mainly eosinophils).